List of Excipients in Branded Drug TAGITOL V

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
E-Z-EM Canada Inc	TAGITOL V	barium sulfate	32909-814	ANHYDROUS CITRIC ACID
E-Z-EM Canada Inc	TAGITOL V	barium sulfate	32909-814	CARBOXYMETHYLCELLULOSE SODIUM
E-Z-EM Canada Inc	TAGITOL V	barium sulfate	32909-814	DIMETHICONE 1000
E-Z-EM Canada Inc	TAGITOL V	barium sulfate	32909-814	DIMETHICONE 350

TAGITOL V Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

TAGITOL V is a ready-to-use oral barium sulfate suspension marketed by Bracco Diagnostics for radiographic examination of the colon, including computed tomography colonography. Its commercial value depends less on the active ingredient, which is an established inorganic contrast medium, than on suspension stability, dose uniformity, patient acceptability, packaging, and procedure workflow. The strongest excipient opportunities are in low-sedimentation formulations, improved palatability, preservative optimization, and differentiated dosing formats.

What is TAGITOL V and how is it used?

TAGITOL V contains barium sulfate at 30% weight/volume and is administered orally before imaging procedures to label residual fecal material and intestinal contents. The product is supplied as a suspension rather than a solution because barium sulfate is practically insoluble in water.

Attribute	TAGITOL V
Active ingredient	Barium sulfate
Strength	30% w/v oral suspension
Dosage form	Ready-to-use oral suspension
Route	Oral
Manufacturer	Bracco Diagnostics Inc.
Primary use	Radiographic examination of the colon
Clinical setting	Radiology and computed tomography imaging
Product type	Diagnostic radiopaque contrast agent
Key formulation problem	Maintaining uniform barium dispersion during storage and dosing

The FDA labeling emphasizes shaking before administration and identifies gastrointestinal adverse reactions, including nausea, vomiting, abdominal pain, diarrhea, and constipation. The formulation must therefore balance physical stability with acceptable mouthfeel and tolerability. [1]

What excipients are used in TAGITOL V?

TAGITOL V uses a conventional suspension architecture built around a viscosity modifier, wetting and texturizing agents, buffering components, sweetening agents, preservatives, flavoring, and purified water. Public product information identifies inactive ingredients that include carboxymethylcellulose sodium, citric acid, glycerin, methylparaben, potassium sorbate, sodium citrate, sorbitol, xanthan gum, flavoring, and water. [1,2]

The precise quantitative composition and manufacturing order are not generally disclosed in the commercial label. That limits direct assessment of formulation equivalence and supplier-level exposure.

Excipient category	Reported TAGITOL V components	Functional role
Suspension and viscosity system	Sodium carboxymethylcellulose; xanthan gum	Reduces sedimentation and supports redispersibility
Humectant and texture modifier	Glycerin	Improves mouthfeel and helps control water activity
Sweetener and osmotic modifier	Sorbitol	Reduces bitterness and supports palatability
Buffer system	Citric acid; sodium citrate	Controls pH and supports preservative and stability performance
Preservatives	Methylparaben; potassium sorbate	Controls microbial growth in the multidose or opened-product environment
Flavor system	Commercial flavoring components	Improves patient acceptability
Vehicle	Purified water	Continuous phase for the suspension

The excipient system is commercially important because barium sulfate has high density and tends to settle. A formulation with inadequate yield stress can produce concentration differences between the first and last doses. Excessive viscosity creates a separate problem: poor pourability, difficult administration, and reduced patient acceptance.

How does the TAGITOL V excipient system affect product performance?

Suspension stability

Sodium carboxymethylcellulose and xanthan gum provide complementary rheological behavior. Carboxymethylcellulose increases continuous-phase viscosity, while xanthan gum can support a more structured suspension with shear-thinning behavior. The target is a product that remains stable at rest but flows under shaking, pouring, or oral administration.

Important performance tests include:

• Sedimentation volume after accelerated and long-term storage
• Redispersibility after defined standing periods
• Assay uniformity by dose or container location
• Viscosity at multiple shear rates
• Pourability through the marketed container
• Particle-size distribution after storage
• Resistance to caking or hard sediment formation

For TAGITOL V, redispersibility is more commercially relevant than simple viscosity. A very thick product may remain physically stable but create operational problems in radiology departments.

Palatability

Barium suspensions can have a chalky texture and residual mouth coating. Sorbitol, glycerin, and flavoring address sweetness, lubrication, and taste perception, but these excipients can create trade-offs. Sorbitol may increase gastrointestinal discomfort in sensitive patients, while excessive glycerin can affect viscosity and mouthfeel.

A practical reformulation strategy would test:

1. Lower chalkiness through particle-size and surface-treatment control.
2. Flavor systems with lower aftertaste.
3. Reduced sweetness with improved masking rather than higher sorbitol concentration.
4. Lower-viscosity dosing while preserving suspension stability.
5. Single-use packaging that minimizes the need for prolonged standing after opening.

Microbiological control

The combination of methylparaben and potassium sorbate indicates a preservation strategy that relies on both preservative activity and pH control. Citric acid and sodium citrate can influence the fraction of preservative present in active form.

Commercial development should evaluate:

• Preservative efficacy under USP <51>
• Compatibility with container materials
• Adsorption or partitioning into plastic packaging
• Stability across the labeled storage range
• Microbial quality after simulated opening and repeated dosing
• Impact of preservative reduction on shelf life

A preservative-free version could have market value if supplied in unit-dose containers, but it would require a different packaging and microbiological-control strategy.

What formulation patents protect TAGITOL V?

Public labeling identifies the formulation and manufacturing characteristics but does not establish a complete patent estate. TAGITOL V should not be treated as protected by formulation patents solely because it is a branded barium sulfate product.

The relevant intellectual-property categories are:

IP category	Potential scope	Commercial relevance
Composition patents	Specific excipient ratios, rheology systems, or particle-size distributions	Could limit close-copy formulations
Process patents	Milling, wetting, homogenization, deaeration, or filling methods	May create manufacturing barriers
Packaging patents	Single-use bottles, dosing systems, or container-closure combinations	Can protect workflow differentiation
Method-of-use patents	Colon labeling, CT colonography preparation, or specific imaging protocols	May affect use-specific market positioning
Trademark rights	TAGITOL V brand and trade dress	Supports branded commercial protection
Regulatory exclusivity	FDA-recognized exclusivity periods, if applicable	Must be confirmed through FDA records

No reliable conclusion on active TAGITOL V formulation patents, expiration dates, or Orange Book listings should be made from the prescribing information alone. Barium sulfate products can have complex regulatory records because different products may be approved through different FDA pathways.

What is the FDA regulatory status of TAGITOL V?

TAGITOL V is an FDA-approved prescription diagnostic product. Its label addresses oral administration, contraindications, warnings concerning gastrointestinal perforation or obstruction, and handling requirements. [1]

The product is not a biologic, so biosimilar analysis is not relevant. The main competitive regulatory pathways are:

• A 505(b)(2) application for a differentiated barium sulfate formulation
• An abbreviated or product-specific pathway where applicable
• A new drug application for a materially differentiated diagnostic formulation
• Contract-manufactured or private-label products based on an approved formulation

Regulatory risk is concentrated in product quality and clinical-use performance. A competing product would need to demonstrate that changes in excipients, concentration, dosing volume, or administration instructions do not compromise diagnostic performance or patient safety.

How many patents cover TAGITOL V?

The number of enforceable patents covering TAGITOL V cannot be established accurately from public product labeling alone. Patent-counting should distinguish between:

• Patents assigned to Bracco Diagnostics
• Patents assigned to affiliates or earlier corporate entities
• Expired patents
• Continuations and divisionals
• Foreign counterparts
• Patents that claim barium sulfate generally
• Patents that claim the specific commercial product or indication

A meaningful freedom-to-operate review would require a current patent-family search across the United States, Europe, Canada, Japan, China, and other major markets. It would also need claim-chart analysis against the actual excipient ratios, particle characteristics, filling process, and packaging configuration.

What excipient opportunities exist around TAGITOL V?

Reduced-volume formulations

Patient preparation can be burdensome because oral contrast products may require multiple administrations. A lower-volume, higher-concentration product could reduce procedure burden, but it would need to preserve radiopacity, suspension stability, and gastrointestinal tolerability.

The commercial opportunity is strongest where radiology providers prioritize faster preparation and better patient throughput.

Unit-dose packaging

Unit-dose bottles or premeasured sachets could reduce dosing errors and simplify radiology workflow. Packaging development could also support preservative reduction or elimination.

Potential advantages include:

• Lower contamination risk
• Simplified inventory control
• Reduced shaking and transfer steps
• Easier patient instructions
• Better traceability by procedure

The main barriers are packaging cost, shipping weight, container compatibility, and stability validation.

Improved taste and texture

Taste and mouthfeel are direct commercial differentiators in oral diagnostic products. A new flavor platform, reduced chalkiness, or lower-residue formulation could support hospital formulary adoption even when imaging performance is similar.

A differentiated product would need objective testing involving:

• Sensory acceptability
• Completion rate
• Nausea and vomiting incidence
• Patient preference
• Radiologist assessment of bowel labeling
• Procedure cancellation or delay rates

Preservative optimization

A lower-preservative or preservative-free formulation could appeal to institutions seeking simpler excipient profiles. The most credible path would pair the formulation with a single-use container rather than rely only on a new preservative system.

Supply-chain substitution

The excipients used in TAGITOL V are generally established pharmaceutical ingredients with multiple potential suppliers. The highest supply-chain risks are likely to arise from:

• Pharmaceutical-grade xanthan gum consistency
• Sodium carboxymethylcellulose viscosity variation
• Flavor-system qualification
• Preservative compatibility
• High-quality barium sulfate particle-size control
• Container-closure performance

Supplier changes would require comparability testing because excipient grade can alter viscosity, sedimentation, redispersibility, and microbial performance.

How does TAGITOL V compare with other barium sulfate products?

TAGITOL V competes with other oral barium sulfate suspensions and imaging-preparation products. The relevant comparison is not simply barium concentration. Buyers evaluate the full procedure:

Commercial factor	TAGITOL V implication
Barium concentration	Determines radiopacity and dosing volume
Viscosity	Affects pourability and patient experience
Sedimentation	Determines dose uniformity and preparation burden
Flavor	Influences completion and patient acceptance
Packaging	Affects nursing and radiology workflow
Shelf life	Determines inventory economics
Price per procedure	Drives formulary and purchasing decisions
Imaging performance	Determines clinical substitution risk

A competing product with the same active ingredient may still require substantial development if its excipient system produces different coating, sedimentation, or fecal-tagging performance.

What generic entry risks exist for TAGITOL V?

Generic or follow-on entry risk is moderate at the active-ingredient level but more complex at the finished-product level. Barium sulfate is widely available, yet a commercially viable substitute must match critical quality attributes and fit existing imaging protocols.

Potential entry scenarios include:

1. A direct suspension copy with similar concentration and excipients.
2. A differentiated 505(b)(2) product with lower volume or improved taste.
3. A hospital-compounded or locally prepared alternative, where permitted.
4. A private-label product manufactured by a contract development and manufacturing organization.
5. A product focused on CT colonography or another specific imaging workflow.

The most likely barriers are regulatory comparability, physical stability, packaging economics, and clinical adoption rather than ingredient scarcity.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can target TAGITOL V-type products through performance-based offerings rather than commodity pricing. The most valuable propositions are:

• Low-variability xanthan gum and carboxymethylcellulose grades
• Prequalified preservative systems
• Taste-masking platforms
• Ready-to-use rheology packages
• Technical support for suspension scale-up
• Container-compatible preservative systems
• Single-use packaging and filling services
• Stability-indicating analytical methods

A supplier that can demonstrate improved redispersibility at lower viscosity has a stronger commercial position than one offering only a lower unit price.

What is the revenue exposure and market outlook?

Product-specific revenue for TAGITOL V is not reliably disclosed in public filings. The addressable market is tied to colon imaging volume, CT colonography adoption, radiology department purchasing, and the use of oral contrast for fecal tagging.

Revenue exposure is sensitive to:

• Loss of hospital contracts
• Product shortages
• Competitor pricing
• Reimbursement and procedure volume
• Adoption of alternative bowel-preparation protocols
• Patient-completion rates
• Changes in CT colonography practice

Because barium sulfate is a low-cost active ingredient, commercial differentiation depends on product reliability, workflow efficiency, and patient acceptance. Excipient innovation can create pricing power only when it produces measurable reductions in preparation time, failed administrations, adverse effects, or procedure delays.

Key Takeaways

• TAGITOL V is a 30% w/v oral barium sulfate suspension marketed by Bracco Diagnostics.
• Its excipient strategy relies on carboxymethylcellulose, xanthan gum, glycerin, sorbitol, citric acid, sodium citrate, methylparaben, potassium sorbate, flavoring, and water.
• The main formulation challenge is maintaining uniform barium dispersion without making the product excessively viscous.
• The strongest commercial opportunities are improved palatability, lower-volume dosing, unit-dose packaging, preservative optimization, and workflow simplification.
• Barium sulfate is widely available, but finished-product substitution requires control of suspension stability, dosing uniformity, radiopacity, tolerability, and packaging.
• TAGITOL V patent count, expiration dates, Orange Book listings, and litigation exposure require a separate current patent-family and FDA-record review.
• Biosimilar risk does not apply because TAGITOL V is a small-molecule diagnostic product, not a biologic.
• Excipient suppliers have the greatest leverage when they offer validated performance improvements rather than commodity ingredients.

FAQs

Is TAGITOL V a liquid solution or suspension?

TAGITOL V is a ready-to-use oral suspension. Barium sulfate remains dispersed in the liquid vehicle and must be shaken before administration.

Can TAGITOL V be reformulated without changing the active ingredient?

Yes, but changes to viscosity modifiers, sweeteners, preservatives, flavoring, particle characteristics, or packaging can affect stability, dosing uniformity, tolerability, and regulatory comparability.

Which excipient is most important for TAGITOL V suspension stability?

Sodium carboxymethylcellulose and xanthan gum are central to suspension structure and redispersibility. Their grade, concentration, hydration, and processing conditions can materially change performance.

Could a preservative-free TAGITOL V substitute be commercially viable?

Potentially. The most practical design would combine preservative reduction or elimination with unit-dose packaging and validated microbiological control.

Is a TAGITOL V generic likely to compete mainly on price?

Price would matter, but workflow and patient acceptance are significant differentiators. A product with better redispersibility, taste, packaging, or lower dosing volume could compete without being the lowest-priced option.

References

1. U.S. Food and Drug Administration. (n.d.). TAGITOL V (barium sulfate) oral suspension: Prescribing information. Bracco Diagnostics Inc.

2. National Library of Medicine. (n.d.). DailyMed: TAGITOL V- barium sulfate suspension. U.S. National Library of Medicine.